ArticleBMC cancer2026
Development and validation of a SHAP-explainable preoperative predictive model for microvascular invasion in hepatocellular carcinoma.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) exhibits high recurrence rates despite curative treatments. Microvascular invasion (MVI) is a key predictor; however, current diagnostic methods are invasive and delayed. We aimed to develop explainable machine learning models for non-invasive, preoperative MVI prediction.
methodsWe retrospectively analysed 308 patients with HCC (132 MVI-positive and 176 MVI-negative) who underwent curative hepatectomy from January 2020 to December 2023, randomly divided into training (n = 216) and validation (n = 92) cohorts (7:3 ratio). Independent risk factors were identified using univariate and multivariate logistic regression analyses. The least absolute shrinkage and selection operator (LASSO) regression was used to select predictive features. Ten machine learning models were constructed and evaluated using receiver operating characteristic (ROC), calibration, and decision curves. Model explainability was assessed using SHapley Additive exPlanations (SHAP).
resultsHepatitis viral load, alpha-fetoprotein, gamma-glutamyl transferase level, tumour size, and radiogenomic venous invasion (RVI) were significant independent risk factors for MVI. LASSO regression identified 12 key features. The extreme gradient boosting (XGBoost) model performed best, with a training set area under the ROC curve (AUC) of 0.852. The accuracy, sensitivity, specificity, and F1 score were 0.792, 0.812, 0.775, and 0.776, respectively. The validation set AUC was 0.815. The accuracy, sensitivity, specificity, and F1 score were 0.750, 0.677, 0.805, and 0.700, respectively. SHAP revealed hepatitis viral load, RVI, alpha-fetoprotein, tumour size, and pseudocapsule integrity as the most influential predictors.
conclusionThe XGBoost model accurately predicted MVI preoperatively in HCC, with SHAP-based interpretability supporting personalised surgical decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.